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Abstract
Background: In 2011, family planning (FP) services were integrated at Martin Preuss Centre (MPC), in urban Lilongwe,
Malawi. To date, no previous study evaluated pregnancy rates among HIV-positive women after the integration of FP
services into HIV care at the facility. In this study, we investigated whether integration of FP services into HIV clinical
care led to increased use of contraceptives and decreased pregnancy rates.
Methods: This was a retrospective cohort analysis of HIV-positive women from 15 to 49 years of age who accessed
antiretroviral therapy (ART) services at MPC. Ascertainment of FP needs, contraceptive methods and pregnancy status
were done at ART initiation, and at each ART follow-up visit. Women were offered a wide range of contraceptive
methods. Outcomes of interest were contraceptive use and rate of pregnancy. Incident pregnancy was ascertained
through patient self-reports during clinic consultation. Trends of contraceptive use and pregnancy rates were analyzed
using chi-square (χ2).
Results: A total of 10,472 women were included in the analysis and contributed 15,700 person-years of observation.
Contraceptive use among all women receiving ART increased from 28% in 2012 to 62% in 2016 (p < 0.001). A total of
501 pregnancies occurred, including 13 multiple pregnancies, resulting in an overall pregnancy rates of 3.2 per 100
person-years. Rates of pregnancy decreased from 6.8 per 100 person-years in 2012 to 1.3 per 100 person-years in 2016
(p < 0.001).
Conclusion: Integration of FP services into HIV care resulted in increased contraceptive use and, subsequently,
decreased pregnancy rates in women receiving ART. HIV programs should consider offering FP services to women
who are receiving ART.
Keywords: Family planning services, Integration, Contraceptives, HIV clinical care, Antiretroviral therapy,
Pregnancy rates
Plain English summary
Women living with HIV appear to have a higher rate of
unintended pregnancy (51–90%), compared to global es-
timates of other women (38%). Most frequently, family
planning services are not integrated into HIV services;
therefore, HIV-positive women typically must visit
separate HIV clinics and reproductive health clinics to
access both services. Integrating family planning services
into HIV care may address some challenges faced by
HIV-infected women in accessing their preferred contra-
ceptive methods.
In 2011, family planning (FP) services were integrated
into HIV care at Martin Preuss Centre (MPC) in urban
Lilongwe, Malawi. In this study, we analyzed data col-
lected during antiretroviral therapy (ART) patient visits
at the HIV clinic. The study demonstrated that integrat-
ing family planning services into HIV care led to an
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increased use of contraceptives from 28% in 2012 to
62% in 2016 among women receiving ART and preg-
nancy rates decreased by 66%.
With the demonstrated reduction in pregnancy rates,
the evidence supporting the need to integrate family
planning services into HIV care is strong. HIV programs
should consider providing reproductive health services
to HIV-positive women.
Background
In 2016, an estimated 14.8 million women were living with
HIV in sub-Saharan Africa [1]. With a total fertility rate of
4.9 births per woman, sub-Saharan Africa has the highest
fertility rates in the world [2]. Approximately one-quarter
of women in sub-Saharan Africa do not use modern con-
traceptives [3]. In Malawi, specifically, the total fertility
rate is 4.4 births per woman; about 41% of pregnancies are
unintended [4]. Unintended pregnancies are a public
health issue. Among HIV-positive women, unintended
pregnancy increases the risk of vertical transmission of
HIV [5], HIV-related maternal morbidity [6] and mental
health problems [7]. Although some gains have been made
to prevent unintended pregnancy, HIV-positive women
still face challenges in accessing family planning (FP) ser-
vices. Usually, FP services are mostly provided in clinics
that are not connected to HIV clinics, therefore, HIV-
positive women typically visit separate HIV clinics and re-
productive health clinics to access both services.
Providing FP services within HIV clinical care offers an
opportunity to address unmet contraceptive needs and re-
duce the risk of unintended pregnancy among women liv-
ing with HIV [8, 9]. Adding to the growing body of
evidence for the need to integrate FP services into HIV
care, a study at Martin Preuss Centre (MPC) in urban
Malawi reported an overall pregnancy incidence of 9.3/
100 person-years between 2007 and 2010, and showed
how the total fertility rate among HIV-infected women
reverted to that of the average urban population in Malawi
after 6 months on antiretroviral therapy (ART) (total fer-
tility rate 3.9) [10]. MPC introduced provider-initiated FP
service following the implementation of the 2011 Malawi
integrated clinical HIV guidelines [11]. Accordingly, MPC
began to routinely provide condoms to all adults receiv-
ing ART and offer at least a standard injectable contracep-
tive (depot medroxyprogesterone Acetate (DMPA))
during ART visits to women. Women who preferred other
contraceptives were referred to a neighboring, external re-
productive health unit for contraceptives. Efforts to imple-
ment more integrated FP services within MPC were
initiated in early 2015, resulting in an array of FP methods
(including oral contraceptive pills, DMPA, copper intra-
uterine devices, etc.) being offered within the ART clinic.
To date, no study evaluated pregnancy rates among
HIV-positive women after the integration of FP services
at MPC. This retrospective cohort study investigated
pregnancy rates and contraceptive use among HIV-
infected women accessing ART at the clinic. We com-
pared pregnancy rates among women on ART to preg-
nancy rates observed in urban women in the country as
whole.
Methods
Study design, population and setting
This retrospective cohort study used routine programme
data collected at a public ART clinic, MPC, at Bwaila
Hospital in urban Lilongwe, Malawi. All HIV-infected
women aged 15 to 49 years who initiated ART between
January 2012 and December 2016 were included in the
study. We excluded (i) all HIV-positive women who reg-
istered for HIV care, but did not start ART, due to in-
consistent pregnancy information among pre-ART
patients, (ii) women who had less than 1 month of ART
follow-up and (iii) women who were pregnant at ART
registration and were lost from care within 3-months
after delivery.
The clinic uses a real-time, point of care, electronic
medical record system (EMRs) for management of HIV-
positive people who are receiving ART [12]. Data for this
analysis were obtained from the EMR system at MPC. In
December 2016, MPC had approximately 22,000 HIV-
positive people on ART (10,887 (49%) women of repro-
ductive age) with an average of 450 attendances each
day.
Data collection through EMRs
All HIV-infected individuals who reported to the ART
clinic were registered for HIV care in the EMRs. During
the study period, patients were initiated on ART based
on WHO clinical staging (stages 3 or 4) or CD4 cell
count measurement below certain thresholds if they had
WHO stages 1 or 2 conditions [11, 13]. CD4 cell count
threshold for ART initiation changed over the study
period, following these guidelines: ≤ 350 cells/μl between
2012 and 2013 and CD4 cell counts ≤ 500 cells/μl from
2014 to June 2016 [11, 13]. Starting July 2016, Malawi’s
HIV program implemented a test and treat policy that
recommended ART initiation for HIV-infected individ-
uals regardless of any clinical or immunological status
[14]. Once initiated on ART, routine visits were sched-
uled monthly during the first six months on ART and
every two or three months thereafter if there were no
clinical complications and adherence was good. Self-
reported pregnancy status was ascertained at ART initi-
ation, and then at each ART follow-up clinic visit. FP
needs and contraceptive methods were recorded in the
EMRs at each clinic visit.
ART program outcomes were recorded at every visit
and classified as “alive on ART”, “died”, “loss to follow-
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up” (LTFU) (missed a clinic appointment by at least two
months), “transfer-out” and “stopped ART”.
Data management and statistical analysis
Contraceptive use was defined as using any form of
contraceptive at the time of ART clinic visit including
condoms and traditional methods. Women who were
not sexually active were included in the denominator be-
cause (i) sexual activity status may change within a short
time and (ii) women might have falsely reported not be-
ing sexually active due to the cultural sensitivity of dis-
cussing their sexual life. Use of long-acting reverse
contraceptives (intrauterine devices and implants) and
permanent contraceptives (tubal ligation and vasectomy)
were classified as “more effective contraceptives” [15]
and other contraceptives were condoms, DMPA and oral
contraceptives.
The primary outcome was incident pregnancy through
patient self-reports during clinic consultation. Incident
pregnancy was defined as either an episode of pregnancy
reported during ART treatment for women who were
not pregnant at ART initiation, or any subsequent epi-
sodes of pregnancy for women who were pregnant at
ART initiation. Regardless of their contraceptive use,
women entered into the observation period at ART initi-
ation if they were not pregnant at ART initiation or
3 months after delivery if they were pregnant at ART
initiation. Women who transferred their HIV care from
another facility were considered to come under observa-
tion when they first registered at MPC. Follow-up ended
either at the time of death, LTFU or the censoring date
(31st December 2016).
Descriptive statistics were used to report contraceptive
use and pregnancy rates. Trends of contraceptives use
and pregnancy were analyzed using chi-square (χ2).
Total fertility rate (TFR) of the study population was
compared to the TFR in women in urban general popu-
lation as estimated by the 2015–2016 Malawi Demo-
graphic Health Survey (MDHS) [4]. According to
MDHS, TFR is defined as the number of children who
would be born per woman if she was to pass through
the childbearing years bearing children according to a
current schedule of age-specific fertility rates. We used
TFR rather than standardized fertility rate because it is
the most widely used measure of fertility and unaffected
by age composition.
Results
Of 13,565 women who accessed ART services at MPC,
3093 (23%) were excluded from the study because their
ART follow-up was less than 1 month or they were preg-
nant at ART registration and were lost from HIV care
within 3-month after delivery. A total of 10,472 (77%)
women were included in the analysis and contributed
95,644 clinical visit observations. Median age at ART
initiation was 29 [inter-quartile range (IQR): 24–34]
years. At ART initiation, 7597 (75%) had WHO clinical
stage 1 or 2 conditions; 2113 (21%) had stage 3 condi-
tions; 475 (4%) had stage 4 conditions; and 287 (3%) had
no WHO clinical staging information (Table 1). Of the
2588 (25%) with baseline CD4 cell count data, the me-
dian CD4 count at ART initiation was 235 cells/mm3
(IQR: 132–332).
Contraceptive use
Trends in contraceptive use were analyzed by calendar
year of implementation of FP services and follow-up
time. Contraceptive use among all women receiving
ART increased from 28% in 2012 to 62% in 2016 (p <
0.001) (Table 2). At baseline, 5368 (51%) women were
assessed for current FP use: 1679 (31%) indicated using
contraceptives at baseline. Of those, 800 (50%) reported
using DMPA, 74 (5%) oral contraceptives, 458 (29%)
more effective methods and 262 (16%) condoms. Infor-
mation on contraceptive methods was missing for 85
(5%) women. At two years of observation, 1810 (60%)
were using contraceptive methods; 759 (42%) were using
DMPA, 51 (3%) oral contraceptives, 490 (27%) other ef-
fective methods and 365 (20%) condoms. Contraceptive
methods were not recorded in 145 (8%) women.
Pregnancy rates
A total of 501 pregnancies occurred, including 13 multiple
pregnancies, during 15,700 person-years of observation.
Overall pregnancy rate was 3.2 per 100 person-years of
observation time. Pregnancy rates decreased from 6.8 per
100 person-years in 2012 to 1.3 per 100 person-years in
2016 (p < 0.001) (Table 2). Women who became pregnant
after starting ART were younger than their non-pregnant
counterparts (median age 26 vs. 29 years; p < 0.001). Dur-
ing follow-up time, pregnancy rates remained stable at 3.1
per 100 person-year (Fig. 1). However, cumulative preg-
nancy rates at 6-, 12-, 24- and 36- months of observation
were 1.6% (95% CI 1.29–1.96), 3.5% (95% CI 3.09–4.05),
6.2% (95% 5.57–6.90) and 10% (95% CI 9.07–11.04), re-
spectively. Overall, the TFR of women on ART (TFR 0.9)
was lower than TFR of women in the general urban popu-
lation (TFR 3.0).
Discussion
In this retrospective cohort study, contraceptive use in-
creased with time of follow-up and increasing year of im-
plementation of integrated FP services. The high, post-
intervention contraceptive use resulted in a lower overall
pregnancy rates of 3.2 per 100 person-years compared to
9.3 per 100 person-years reported in the pre-intervention
study [10]. Pregnancy rates decreased steadily during the
five-year study period. The TFR of women in the study
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was also lower than both the TFR of the general popula-
tion of urban Malawian women [4] and the TFR among
pre-intervention women in 2010 (TFR 3.1) [10], suggest-
ing the impact of the integrated, comprehensive FP ser-
vices in HIV-infected women.
Overall fertility rates declined in Malawi over the past
six years: the TFR decreased by 25% between 2010 and
2016 among urban population women in Malawi [4].
Although some of the drop in TFR observed in the study
cohort may likely be due to population-level trends, the
steep TFR decrease of 71% among study women cannot
be entirely explained by societal factors, alone. Rather,
the comprehensive integration of FP services into HIV
care may have complemented women’s increased desire
to use contraceptives methods. A third of women in the
study were using contraceptives at baseline; however, the
proportion of women that used contraceptives over
follow-up period peaked to 62%, suggesting that re-
peated counseling on FP may have improved use of
contraceptive. Provision of FP within HIV clinical care
may also have addressed some challenges faced by HIV-
infected women in accessing their preferred contracep-
tive methods. The provision of FP and HIV-related
services in one clinic visit also minimizes transportation
costs and wait times that a patient would have incurred
during multiple clinic visits. Given the high uptake of
contraceptives in women receiving ART, public HIV
clinics should consider integrating comprehensive family
planning services in order to effectively reduce unin-
tended pregnancies.
Table 2 Contraceptive use and pregnancy rates by calendar years, among HIV-infected women receiving ART at Martin Preuss
Centre, Lilongwe, Malawi (N = 10,472)
2012 2013 2014 2015 2016 P-value for trend
Number of women 1590 3295 4666 5925 7463
Clinic review visits 7663 15,687 21,297 26,474 24,523
Assessment of contraceptive use 6615
(86%)
13,590
(87%)
18,174
(85%)
22,103
(83%)
22,008
(90%)
Contraceptive use 28% 49% 59% 61% 62% < 0.001
More effective contraceptivesa 26% 26% 28% 28% 27% < 0.001
Pregnancy rates /100 person-years 6.8
(5.2–8.8)
4.1
(3.4–5.1)
4.0
(3.4–4.7)
3.3
(2.8–3.8)
1.3
(1.0–1.7)
aMore effective contraceptive methods are implants; intrauterine devices, tubal ligation and vasectomy
Table 1 Baseline characteristics of women who accessed ART at Martin Preuss Centre in Lilongwe, Malawi, between January 2012
and December 2016
Characteristics Women: # (%) Number of pregnancies Observed rate per
100 person-years
(95% confidence interval)
Age ART initiationa
15–19 734 (7%) 41 4.4 (3.3–6.0)
20–24 2151 (21%) 144 5.1 (4.3–6.0)
25–29 2806 (27%) 180 4.2 (3.7–4.9)
30–34 2384 (23%) 98 2.6 (2.2–3.2)
35–39 1328 (13%) 32 1.4 (1.0–2.0)
40–44 701 (7%) 5 0.4 (0.2–1.0)
45–49 325 (3%) 0 0 –
WHO clinical stage at ART initiationb
1 or 2 7597 (75%) 380 3.3 (3.0–3.7)
3 2113 (21%) 90 2.8 (2.3–3.4)
4 475 (4%) 24 2.8 (1.9–4.3)
CD4 count (cells/mm3) at ART initiationc
< 250 1390 (54%) 81 3.1 (2.5–3.8)
250 to 349 662 (26%) 43 3.4 (2.5–4.6)
≥ 350 536 (21%) 14 2.2 (1.3–3.8)
a43 women were less than 15 years at ART initiation; b287 women had no WHO clinical stage at ART initiation; c7,884 women had no CD4 count at ART initiation
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We found an overall contraceptive use of 62% in 2016.
As compared to our result, some recent studies among
women receiving ART in Ethiopia, Nigeria and Ghana
reported a lower contraceptive rate, 44%, 36% and 43%,
respectively [16–18], while a study in Zambia reported
higher contraceptive use of 69% [19]. Unlike our study,
however, family planning services were not fully integrated
in HIV clinical care in these studies and most preferred
methods were male condoms, except in Ethiopia. These
comparisons highlight variations of contraceptive ser-
vice delivery and contraceptive uptake among HIV-
positive women who are receiving HIV-related care in
sub-Saharan Africa.
Although our findings are similar to a South African
study that reported pregnancy rates of 3.95 per 100
person-years [20], it contrasts with other recent studies
reporting higher rates of pregnancy among women on
ART in sub-Saharan Africa [21, 22]. These contrasts may
result from the differences in the availability of FP services
or the level of FP integration into HIV services. At MPC,
several steps were taken to ensure the successful integra-
tion of FP services in HIV clinical care. First, patients were
informed about availability of FP services through both
oral and visual methods, increasing their awareness of FP
services through daily patients’ education sessions. Sec-
ond, providers were well trained in reproductive health
services. Their clinical service provision was also sup-
ported by EMRs that guided service provision and clinical
decisions during each clinic visit. These steps, which may
not have been applied elsewhere, likely led to the attain-
ment of full FP integration at MPC.
This study has several limitations. First, the assessment
of pregnancy was based upon self-reports, which is known
to be affected by social desirability bias and depended on
whether the women knew they were pregnant or not at
the time of the clinic visit. Second, this study used routine
data from the HIV clinical care and some information was
not captured in EMRs due to unavailability of electrical
power at the time of the clinic visit. Information on
contraceptive use was not available in 13% of the women
that were supposed to be assessed. Lastly, use of EMRs
combined with sound management and implementation
efforts to prepare providers on FP provision and encour-
age client uptake at MPC may not be easily applied else-
where, potentially decreasing the success of FP integration
in other settings. Despite these limitations, our findings
support the provision of comprehensive FP services to
HIV-infected women can reduce unintended pregnancies.
Conclusion
The improved FP access and availability due to FP integra-
tion into HIV care led to increased contraceptive uptake
and, subsequently, decreased pregnancy rates among HIV-
infected women receiving ART. Other high HIV prevalence
settings in sub-Saharan Africa should consider integrating
FP into routine HIV care to improve reproductive health
outcomes.
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